(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

F5 and NextGen Healthcare Post Upbeat Earnings, Inter Parfums Q2 Revenue Beats

July 25th, 2023

F5, Inc. (Nasdaq: FFIV) reported third-quarter fiscal 2023 earnings per share (EPS) of $3.21 and revenue of $702.64 million, surpassing the consensus estimate of $2.86 on revenue of $699.39 million for the period. $FFIV is currently trading at $16. Read more

Justice Department Files Complaint Against the State of Texas for Illegally Placing Floating Buoy Barrier in the Rio Grande

July 24th, 2023

For Immediate Release Office of Public Affairs Washington D.C. / CRWE PRESS RELEASE / July 24, 2023 - The Justice Department today filed a civil complaint against the State of Texas because the state has built a floating barrier, consisting of bu. Read more

Q2 Earnings: Crown Holdings Miss, Range Resources Beat

July 24th, 2023

Crown Holdings, Inc. (NYSE: CCK) announced second-quarter 2023 earnings per share (EPS) at $1.31, missing the consensus estimate of $1.64. The company expects third-quarter adjusted EPS to be in the range of $1.70 to $1.80, while analysts are project. Read more

Momentum Shift: Domino's Pizza Q2 Earnings Beat; Lam Research In Focus

July 24th, 2023

Domino's Pizza, Inc. (NYSE: DPZ) reported second-quarter 2023 earnings per share (EPS) of $3.08, surpassing the consensus estimate of $3.05.  $DPZ is currently trading at $395.00 in pre-market, up $9.56 (+2.48%) In other news, Lam Research. Read more

Making Waves: PaxMedica In The Spotlight; Bullish View On Outbrain

July 24th, 2023

Shares of PaxMedica, Inc. (Nasdaq: PXMD) surged over 10% in pre-market trading as the company revealed positive top-line data from its PAX-HAT-301 Retrospective Analysis of Suramin Treatment for Stage 1 Trypanosoma Brucei Rhodesiense Human African Tr. Read more

AMC Entertainment Needs Equity Capital: CEO

July 24th, 2023

AMC Entertainment Holdings, Inc. (NYSE: AMC) has faced stockholder class actions filed in the Delaware Court of Chancery, leading to consolidation and settlement efforts. However, this past Friday, the Court declined to approve the settlement as pres. Read more

Fiserv, GSK, CME Group, General Dynamics, and O'Reilly's Earnings: A Preview

July 24th, 2023

On Wednesday, July 26, several major companies are set to announce their financial performance for the second quarter of 2023, including: Fiserv, Inc. (NYSE: FI), a leading provider of financial services technology solutions, will reveal its earni. Read more

Earnings Preview: Union Pacific, AT&T, ADP, and Lam Research in Focus

July 23rd, 2023

On Wednesday, July 26, several companies are expected to release their financial results, including Union Pacific Corporation (NYSE: UNP), a leading railroad company, will announce its second quarter 2023 financial and operating results before the. Read more

Earnings On The Horizon: Snap, Hubbell, PulteGroup, Lamb Weston - A Preview

July 23rd, 2023

Four prominent companies are set to disclose their financial performance on Tuesday, July 25: Snap Inc. (NYSE: SNAP), a leading social media company, will reveal its financial results after the market closes.  Analysts are expecting a loss. Read more

Horizon Therapeutics' Daxdilimab Trial Falls Short on Primary Endpoint

July 23rd, 2023

Horizon Therapeutics plc (Nasdaq: HZNP) reported disappointing results from its Phase 2 clinical trial for daxdilimab in the treatment of systemic lupus erythematosus (SLE), the most common type of lupus. The trial did not show a statistically signif. Read more